Clinical trials
Lymphoma clinical trials
Cancer of the lymphatic system, part of the body’s immune defenses. We’re tracking 1,373 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07272499RecruitingPhase 2
New drug combo for untreated high-risk mantle cell lymphoma
This trial tests a combination of three drugs (orelabrutinib, lisaftoclax, and rituximab) for people with mantle cell lymphoma who have not had treatment before and have high-risk features. The goal is to see if this combination works better than standard treatments.
Shanghai, Shanghai MunicipalityAges 14 years+ - NCT07278921Recruiting
Mosunetuzumab for relapsed follicular lymphoma
This trial tests a drug called Mosunetuzumab for people with follicular lymphoma that has come back or stopped responding after at least two previous treatments. It is available through a compassionate use program for those who have no other options.
MilanAges 18 years+ - NCT07285044RecruitingPhase 2
Home cancer treatment program for Florida panhandle residents
This study tests whether people with certain cancers can safely receive their regular intravenous treatments at home instead of coming to the clinic. It aims to make treatment more convenient and improve satisfaction, especially for those living in the Florida Panhandle.
Jacksonville, FloridaAges 18 years+ - NCT07285590RecruitingPhase 2
Testing pirtobrutinib and rituximab for mantle cell lymphoma
This trial tests a new drug combination (pirtobrutinib plus rituximab) for people with mantle cell lymphoma who have not yet received any treatment and do not have symptoms. The goal is to see if the combination is safe and effective.
Lisbon, Lisbon DistrictAges 18 years+ - NCT07290309Recruiting
Remote exercise program for cancer survivors
This study tests a remote guided exercise program for cancer survivors to see if it helps with recovery and well-being. It is designed for people who have finished their main cancer treatments and are not already exercising a lot.
Fort Collins, ColoradoAges 18 years+ - NCT07299149RecruitingPhase 2
Testing a new triple-drug combination for untreated follicular lymphoma
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
Tianjin, Tianjin MunicipalityAges 18–90 - NCT07300514RecruitingPhase 3
Golidocitinib vs placebo for T-cell lymphoma maintenance
This trial tests if taking golidocitinib pills after first treatment helps keep peripheral T-cell lymphoma from coming back. You'll either get the study drug or a placebo (no active drug), and your doctor will watch how you do.
ShanghaiAges 18 years+ - NCT07309497Recruiting
Geriatric Assessment for Older Adults Before CAR-T or Bispecific Therapy
This trial studies how a simple geriatric assessment (a check-up for older adults) can help predict side effects and outcomes in patients aged 65+ who are about to receive CAR-T cell therapy or bispecific antibody treatment.
BernAges 65 years+ - NCT07313943Recruiting
Study of PAX5-negative Hodgkin-like lymphomas
This study looks at a rare type of lymphoma that looks like Hodgkin lymphoma but lacks a protein called PAX5. The goal is to better understand and diagnose this condition, which can be hard to tell apart from other lymphomas.
TübingenAges 18 years+ - NCT07319676RecruitingPhase 1/Phase 2
Targeted T-cell therapy for relapsed B-cell lymphoma
This trial tests a new type of cell therapy (CAR T) that targets two markers on lymphoma cells, CD19 and CD22. It is for people with aggressive B-cell lymphoma that has not responded to standard treatments.
Singapore, SingaporeAges 10–80 - NCT07343934RecruitingPhase 1
HuCART19-IL18 for relapsed/refractory follicular lymphoma
This trial tests a new type of CAR T-cell therapy (huCART19-IL18) for people with follicular lymphoma that has not responded to or returned after at least two prior treatments. It aims to see if adding IL-18 makes the therapy more effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05954910Recruiting
Study of polatuzumab for real-world DLBCL patients in China
This study looks at how well a drug called polatuzumab works for people with a type of lymphoma (DLBCL) in everyday medical practice in China. It is for patients who are older, have other health problems, or whose lymphoma came back after or did not respond to treatment.
BeijingAges 18 years+ - NCT07353840Recruiting
Personalized treatment for T-cell lymphoma after first complete remission
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07355699RecruitingPhase 4
Orelabrutinib for untreated marginal zone lymphoma
This trial tests a new targeted drug (orelabrutinib) with or without another drug that targets CD20 (a protein on some immune cells) for people with untreated marginal zone lymphoma. It aims to see if this combination works better than other treatments and may be an option for those who cannot have radiation.
BeijingAges 18 years+ - NCT07356882Recruiting
Using ctDNA to monitor treatment in young Hodgkin lymphoma patients
This study uses a blood test to detect cancer DNA (ctDNA) in children and young adults with classical Hodgkin lymphoma. The goal is to see if this non-invasive test can help track how well treatment is working.
ParisAges Any age - NCT07368270RecruitingPhase 1
Anti-PD1 armored CAR-T cells for adults with relapsed/refractory DLBCL
This trial tests a new kind of cell therapy that combines CAR-T cells (which find and kill cancer cells) with an anti-PD1 'armor' to boost their power. It is for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to earlier treatments.
SuzhouAges 18 years+ - NCT07369492RecruitingPhase 1
Study of BAFF-R CAR-T cells for CD19-negative B-cell lymphoma
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
SuzhouAges 18 years+ - NCT07371923RecruitingPhase 2
Zanubrutinib combination therapy for newly diagnosed high-risk DLBCL
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07376642RecruitingEarly Phase 1
Testing IMV101 for relapsed B-cell lymphoma
This study tests an experimental drug called IMV101 for people with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to other treatments. It aims to see if the drug is safe and if it can shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07377578RecruitingPhase 3
Rocbrutinib vs other BTK inhibitors for mantle cell lymphoma
This study tests a new targeted therapy called Rocbrutinib against other BTK inhibitors for people with mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see which works better and how safe they are.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07389616RecruitingPhase 2/Phase 3
Preventing lymphoma return after transplant
This trial tests a combination of two drugs (cidabenamine and azacitidine) to help prevent peripheral T-cell lymphoma from coming back after a donor stem cell transplant. It is for patients who are at high risk of progression and have already had a transplant.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT00626496Recruiting
Family study for certain blood and immune disorders
This study looks at families where more than one close, blood-related person has a lymphoproliferative disorder (a group of conditions where the lymph system makes too many abnormal cells). It aims to better understand why these disorders run in families and how they may be inherited or related.
Rochester, MinnesotaAges 18–100 - NCT00006518Recruiting
Tissue samples from people with viral infections or cancer
This study collects tissue and blood samples from people who have or have been exposed to certain viruses (HIV, KSHV, HPV, EBV, or HTLV-1) or who have developed cancer or precancerous skin lesions. The samples help researchers understand how these viruses may lead to cancer.
Bethesda, MarylandAges 18 years+ - NCT00177268Recruiting
Collecting blood and tissue samples in skin diseases research
This study collects blood, urine, and possibly small tissue samples to learn more about cutaneous T-cell lymphoma (CTCL) and either eczema or atopic dermatitis. It may help researchers better understand these skin conditions and improve future treatments.
Pittsburgh, PennsylvaniaAges 18 years+
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma?
- Yes. Clin2 currently lists 1,373 recruiting lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.